Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity in Patients with Ischemic CRVO
يكشنبه, ۲۵ شهریور ۱۳۹۷، ۰۶:۱۴ ق.ظ
Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity
in Patients with Ischemic CRVO
Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity
in Patients with Ischemic CRVO
Fesharaki H, MD
Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity
in Patients with Ischemic CRVO
Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity
in Patients with Ischemic CRVO
Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity
in Patients with Ischemic CRVO
ﻢﺸﭼ ﻪﻠﺠﻣ ﺎﻨﻴﺑ ﻲﻜﺷﺰﭘ- ﻩﺭﻭﺩ ۱۵- ﻩﺭﺎﻤﺷ ۱) ﺰﻴﻳﺎﭘ۱۳۸۸(
ﻢﺸﭼ ﻪﻠﺠﻣ ﺎﻨﻴﺑ ﻲﻜﺷﺰﭘ- ﻩﺭﻭﺩ ۱۵- ﻩﺭﺎﻤﺷ ۱) ﺰﻴﻳﺎﭘ۱۳۸۸(
٨
Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity
in Patients with Ischemic CRVO
Razmjoo H, MD; Kian-Ersi F, MD; Moenei HA, MD; Dehghani AR, MD; Ilanloo MR, MD; Akhlaghi MR, MD;
Rismanchian A, MD; Fesharaki H, MD
Purpose: To determine the effect of intravitreal triamcinolone (IVT) injection on visual acuity in patients
with ischemic central retinal occlusion (CRVO).
Methods: This randomized clinical trial was performed on patients with ischemic CRVO referred to the
retina clinic at Feiz Hospital in 2007-2008. Inclusion criteria were: duration of CRVO less than one month,
normal IOP, no sign of diabetic retinopathy or hypertensive retinopathy, no history of laser therapy and
ocular surgery and vascular diseases. Patients were randomly allocated to two groups: intervention group
(injection of 0.1cc IVT) and control group (no injection). Follow up examinations for all patients were
scheduled 1, 2, 3 and 6 months after injection. The results were analyzed by SPSS13 and t-test.
Results: Overall, 52 patients (22 male and 30 female) entered the study. Mean age was 60.5±9.7 (range: 30-
80) years. Duration of signs was 21±5.5 days in the control group and 19±6 days in the IVT group (P= 0.66).
All patients had signs of ischemic CRVO. Mean baseline visual acuity was 1.75±0.20 logMAR in the IVT
group and 1.91±0.08 logMAR in the control group (P= 0.1). VA improvement in the IVT group was greater
in comparison with the control group at one month (P= 0.019) however this difference was not significant at
other follow-up examinations. In addition, the difference in IOP between before and after the injection was
not significant (P= 0.802).
Conclusion: This study showed that in patients with CRVO, intravitreal injection of triamcinolone, has no
significant long-term effect on visual acuity.
Key Words: Triamcinolone, Central Retinal Artery Occlusion
• Bina J Ophthalmol 2009; 15 (1): 8-12.
(PDF) Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity in Patients with Ischemic CRVO. Available from: https://www.researchgate.net/publication/320840035_Effect_of_Intravitreal_Triamcinolone_IVT_Injection_on_Visual_Acuity_in_Patients_with_Ischemic_CRVO [accessed Sep 16 2018].
ﻢﺸﭼ ﻪﻠﺠﻣ ﺎﻨﻴﺑ ﻲﻜﺷﺰﭘ- ﻩﺭﻭﺩ ۱۵- ﻩﺭﺎﻤﺷ ۱) ﺰﻴﻳﺎﭘ۱۳۸۸(
٨
Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity
in Patients with Ischemic CRVO
Razmjoo H, MD; Kian-Ersi F, MD; Moenei HA, MD; Dehghani AR, MD; Ilanloo MR, MD; Akhlaghi MR, MD;
Rismanchian A, MD; Fesharaki H, MD
Purpose: To determine the effect of intravitreal triamcinolone (IVT) injection on visual acuity in patients
with ischemic central retinal occlusion (CRVO).
Methods: This randomized clinical trial was performed on patients with ischemic CRVO referred to the
retina clinic at Feiz Hospital in 2007-2008. Inclusion criteria were: duration of CRVO less than one month,
normal IOP, no sign of diabetic retinopathy or hypertensive retinopathy, no history of laser therapy and
ocular surgery and vascular diseases. Patients were randomly allocated to two groups: intervention group
(injection of 0.1cc IVT) and control group (no injection). Follow up examinations for all patients were
scheduled 1, 2, 3 and 6 months after injection. The results were analyzed by SPSS13 and t-test.
Results: Overall, 52 patients (22 male and 30 female) entered the study. Mean age was 60.5±9.7 (range: 30-
80) years. Duration of signs was 21±5.5 days in the control group and 19±6 days in the IVT group (P= 0.66).
All patients had signs of ischemic CRVO. Mean baseline visual acuity was 1.75±0.20 logMAR in the IVT
group and 1.91±0.08 logMAR in the control group (P= 0.1). VA improvement in the IVT group was greater
in comparison with the control group at one month (P= 0.019) however this difference was not significant at
other follow-up examinations. In addition, the difference in IOP between before and after the injection was
not significant (P= 0.802).
Conclusion: This study showed that in patients with CRVO, intravitreal injection of triamcinolone, has no
significant long-term effect on visual acuity.
Key Words: Triamcinolone, Central Retinal Artery Occlusion
• Bina J Ophthalmol 2009; 15 (1): 8-12. Received: 10.5.2008 Accepted: 5.5.2009
زراﻳﺑﺎﻲ ﻖﻳرﺰﺗ ﺮﺛاﺮﺗﻳﺴﻣﺎﻴو ﻞﺧاد نﻮﻟﻮﻨﻳهﺮﺘ تﺪﺣ ﺮﺑﻲﻳﺎﻨﻴﺑﺑ ﻴ نارﺎﻤ ﻪﺑ ﻼﺘﺒﻣ
CRVO
1.
Yanoff M, Duker JS. Ophthalmology. 2th ed. St. Louis,
USA: Mosby; 2004: 862.
2.
Green WR, Chan CC, Hutchins GM, Terry JM. Central
retinal vein occlusion: a prospective histopathologic study
of 29 eyes in 28 cases. Retina 2005;25:27-55.
3.
Gass JDM. Macular dysfunction caused by retinal vascular
disease. In: Gass JDM (ed). Stereoscopic Atlas of Macular
Disease. 4th ed. St. louis, Missouri: Mosby; 1997: 437-599.
4.
Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A,
Lelong F, Samama MM. Prognostic factors for retinal vein
occlusion: prospective study of 175 cases. Ophthalmology
1996;103:551-560.
5.
Ghazi NG, Noureddine B, Haddad RS, Jurdi FA, Bashshur
ZF. Intravitreal tissue plasminogen activator in the
management of central retinal vein occlusion. Retina
2003;23:780-784.
6.
Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as
treatment for central retinal vein occlusion. Am J
Ophthalmol 2003;136:814-819.
7.
The central vein occlusion study group. Evaluation of grid
pattern photocoagulation for macular edema in central
vein occlusion: the central vein study group M Report.
Ophthalmology 1995;102:1425-1433.
8.
Sanborn GE, Magargal LE, Jaeger EA. Venous occlusive
disease of the retina. In: Duane's clinical ophthalmology.
Philadelphia: Lippincott Williams and Wilkins; 2004:15.
9.
Lubczyńska A, Kociecki. Inhtravitreal triamcinolone
acetonide injections in the treatment of cystoid macular
edema due to the central or branch retinal vein occlusion.
Klin Oczna 2007;109(4-6):169-72.[Article in Polish]
10.
Williamson TH, O'Donnell A. Intravitreal triamcinolone
acetonide for cystoid macular edema in nonischemic
central retinal vein occlusion. Am J Ophthalmol
2005;139:860-866.
11.
Jonas JB, Hayler JK, Söfker A, Panda-Jonas S. Regression of
neovascular iris vessels by intravitreal injection of
crystalline cortisone. J Glaucoma 2001;10:284-287.
12.
Fong DS, Segal PP, Myers F, Ferris FL, Hubbard LD, Davis
MD. Subretinal fibrosis in diabetic macular edema. ETDRS
report 23. Early Treatment Diabetic Retinopathy Study
Research Group. Arch
Ophthalmol 1997;115:873-877.
13.
Mandava N, Yannuzzi LA. Hypertensive retinopathy. In:
Regillo CD, Brown GC, Flynn HW. Jr, eds. Vitreoretinal
Disease: The Essentials. NewYork: Thieme; 1999:193-196.
14.
Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche
TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid
macular edema: an optical coherence tomography study.
Ophthalmology 2001;108:765-772.
15.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito
CA, Reichel E, et al. Intravitreal triamcinolone for
refractory diabetic macular edema. Ophthalmology
2002;109:920-927.
16.
Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal
injection of triamcinolone for diffuse diabetic macular
edema. Arch Ophthalmol 2003;121:57-61.
17.
Miyake K, Miyake T, Kayazawa F. Blood-aqueous barrier
in eyes with retinal vein occlusion. Ophthalmology
1992;99:906-910.
18.
Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W,
Miyamoto K, Hassessian H, et al. VEGF-initiated blood-
retinal barrier breakdown in early diabetes. Invest
Ophthalmol Vis Sci 2001;42:2408-2413.
19.
Nauck M, Karakiulakis G, Perruchoud AP,
Papakonstantinou E, Roth M. Corticosteroids inhibit the
expression of the vascular endothelial growth factor gene
in human vascular smooth muscle cells. Eur J Pharmacol
1998;341:309-315.
20.
Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit
VEGF-induced vascular leakage in a rabbit model of
blood-retinal and blood-aqueous barrier breakdown. Exp
Eye Res 2005;80:249-258.
21.
Ip M, Kahana A, Altaweel M.Treatment of central retinal
vein occlusion with triamcinolone acetonide: an optical
coherence tomography study. Semin Ophthalmol 2003;18:67-
73.
22.
Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM,
Blodi BA, et al. Intravitreal triamcinolone for the treatment
of macular edema associated with central retinal vein
occlusion. Arch Ophthalmol 2004;122:1131-1136.
23.
Ramezani A, Entezari M, Moradian S, Tabatabaei H,
Kadkhodaei S. Intravitreal triamcinolone for acute central
retinal vein occlusion; a randomized clinical trial. Graefes
Arch Clin Exp Ophthalmol 2006;244:1601-1606.
24.
Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS,
Noureddin BN. Intravitreal triamcinolone for the
management of macular edema due to nonischemic central
retinal vein occlusion. Arch Ophthalmol 2004;122:1137-1140.
25.
Ozdek SC, Aydin B, Gürelik G, Bahçeci U, Hasanreisoğlu
B. Effects of intravitreal triamcinolone injection on macular
edema and visual prognosis in central retinal vein
occlusion. Int Ophthalmol 2005;26:27-34.
26.
Lubczyńska A, Kociecki J. Inhtravitreal triamcinolone
acetonide injections in the treatment of cystoid macular
edema due to the central or branch retinal vein occlusion.
Klin Oczna 2007;109:169-172.
27.
Gelston CD, Olson JL, Mandava N. Macular oedema in
central retinal vein occlusion treated with intravitreal
triamcinolone. Acta Ophthalmol Scand 2006;84:314-318.
28.
Patel PJ, Zaheer I, Karia N. Intravitreal triamcinolone
acetonide for macular oedema owing to retinal vein
occlusion. Eye 2008;22:60-64.
29.
Moschos MM, Brouzas D, Loukianou E, Apostolopoulos
M, Moschos M. Intraocular triamcinolone acetonide for
macular edema due to CRVO. A multifocal-ERG and OCT
study. Doc Ophthalmol 2007;114:1-7.
30.
Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal
triamcinolone acetonide and intraocular pressure. Am J
Ophthalmol 2004;138:740-743.
(PDF) Effect of Intravitreal Triamcinolone (IVT) Injection on Visual Acuity in Patients with Ischemic CRVO. Available from: https://www.researchgate.net/publication/320840035_Effect_of_Intravitreal_Triamcinolone_IVT_Injection_on_Visual_Acuity_in_Patients_with_Ischemic_CRVO [accessed Sep 16 2018].
https://www.researchgate.net/publication/320840035_Effect_of_Intravitreal_Triamcinolone_IVT_Injection_on_Visual_Acuity_in_Patients_with_Ischemic_CRVO
